Compare Enveric Biosciences Inc (ENVB) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs PulteGroup, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while PulteGroup, Inc. trades at $127.64 (market cap $23.89B). The key difference: PulteGroup, Inc. is far larger — about 4490.6× Enveric Biosciences Inc's market cap, and PulteGroup, Inc. pays a 0.83% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PHM | |
|---|---|---|
Market Cap | $5.32M | $23.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $142.56 |
52-Week Low | $1.28 | $108.65 |
Enterprise Value | $408.82K | $23.84B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
PulteGroup (PHM) trades at $127.11, up 2.05% today, with a bullish technical signal and strong profitability metrics including a 12.14% net margin. Recent earnings show mixed results with a Q3 2025 beat but subsequent misses, while cash flow trends improved in 2025. The stock is near its 52-week high of $144.50, reflecting resilience despite housing market headwinds from rising mortgage rates.
Outlook is cautiously optimistic with a consensus price target of $145.20 offering 14% upside, but risks include margin pressure from discounts and rate buydowns. Investment opportunity hinges on execution amid affordability challenges, with analyst sentiment balanced between buy and hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
